Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion

Journal of Investigative Dermatology

Volumn 112, Issue 1, 1999, Pages 78-84

  Sambo, Paola ^a   Jannino, Laura ^a   Candela, Marco ^a   Salvi, Aldo ^a   Donini, Marta ^b   Dusi, Stefano ^b   Luchetti, Michele M ^a   Gabrielli, Armando ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Connective tissue disease; Free radicals; Monocyte; Scleroderma

Indexed keywords

CYTOCHROME C; PHORBOL 13 ACETATE 12 MYRISTATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROTENONE; SUPEROXIDE; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSOL; DISEASE DURATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MONOCYTE; NEUTROPHIL; OXIDATIVE STRESS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SCLERODERMA; ENZYME ACTIVATION; METABOLISM; MIDDLE AGED; SYSTEMIC SCLEROSIS;

ADULT; AGED; ENZYME ACTIVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; NADPH OXIDASE; NEUTROPHILS; SCLERODERMA, SYSTEMIC; SUPEROXIDES; TETRADECANOYLPHORBOL ACETATE;

EID: 0032589789     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1999.00476.x     Document Type: Article

References (52)

1. rac from its inhibitory GDP/GTP exchange protein (rhoGDI) followed by its translocation to the plasma membrane. Biochem J 298:585-591, 1994
2. Bastian RN, Hibbs JB Jr: Assembly and regulation of NADPH oxidase and nitric oxide synthase. Curr Opin Immunol 6:131-139, 1994
3. Belch JJF: Raynaud's phenomenon. Curr Opin Rheumatol 1:490-498, 1989
4. Belch JJF: Raynaud's phenomenon: its relevance to scleroderma. Ann Rheum Dis 50:839-845, 1991
5. Bertani A, Polentarutti N, Sica A, Rambaldi A, Mantovani A, Colotta F: Expression of c-jun protoncogene in human myelomonocytic cells. Blood 74:1811-1816, 1989
6. Black CM, Stephens C. Systemic sclerosis (scleroderma) and related disorders. In: Maddison DJ, Isenberg DA, Woo P, Glass DN (eds). Oxford Textbook of Rheumatology. Oxford: Oxford University Press, 1993, pp. 771-787
7. Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin 10. J Exp Med 174:1549-1555, 1991
8. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
9. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM: Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with Systemic Sclerosis. Arthritis Rheum 38:1060-1067, 1995
10. Bulkley GB: Reactive oxygen mediated and reperfusion injury: aberrant triggering of reticuloendothelial function. Lancet 344:934-936, 1994
11. Casciola-Rosen L, Wigley F, Rosen A: Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implication for pathogenesis. J Exp Med 185:71-79, 1997
12. Chojkier M, Houglum K, Solis-Herruzo J, Brenner DA: Stimulation of collagen gene expression by ascorbic acid in cultured human fibroblasts. A role for lipid peroxidation. J Biol Chem 264:16957-16962, 1989
13. Clark RA, Volpp BC, Leidal KG, Nauseef WM: Two cytosolic components of the human neutrophil respiratory burst oxidase translocate to the plasma membrane during cell activation. J Clin Invest 85:714-721, 1990
14. 2 release by human blood monocytes and mouse peritoneal macrophages. J Immunol Meth 78:323-336, 1985
15. De Leo FR, Quinn M: Assembly of the phagocyte NADPH oxidase: molecular interaction of oxidase proteins. J Leukoc Biol 60:677-691, 1997
16. Del Maestro RF, Thaw HH, Bjork J, Blanker M, Arfors KE: Free radicals as mediators of tissue injury. Acta Physiol Scand 492:43-57, 1980
17. Dusi S, Della Bianca V, Donini M, Nadahni KA, Rossi F: Mechanisms of stimulation of the respiratory burst by TNF in nonadherent neutrophils. Its independence of lipidic transmembrane signaling and dependence on protein tyrosine phosphorylation and cytoskeleton. J Immunol 157:4615-4623, 1996
18. Finch WR, Rodnan GP, Buckingham RB, Prince RK, Winkelstein A: Bleomycin-induced scleroderma. J Rheumatol 7:651-659, 1980
19. Fleischmajer R, Perlish SH, Jay H, Shaw KV, Pirozzi DJ: Skin capillary changes in early systemic scleroderma. Arch Dermatol 111:1553-1557, 1976
20. Gordon S, Clarke S, Greaves D, Doyle A: Molecular immunobiology of macrophages: recent progress. Curr Opin Immunol 7:24-33, 1995
21. Halliwell B: Free radicals, antioxidants, and human disease: curiosity, cause or consequence? Lancet 344:721-724, 1994
22. Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MIV: Micronutrient antioxidant status in patients with Primary Raynaud's Phenomenon and Systemic Sclerosis. J Rheumatol 21:1477-1483, 1994
23. Holt CM, Lindsey N, Moult J, et al: Antibody-dependent cellular cytotoxicity of vascular endothelium: characterization and pathogenic associations in systemic sclerosis. Clin Exp Immunol 78:359-365, 1989
24. Inaunen W, Payne DK, Kvietys PR, Granger DR: Hypoxia/reoxygenation increases the permeability of endothelial cell monolayers: role of oxygen radicals. Free Radic Biol Med 1990:219-223, 1989
25. Kahaleh MB, LeRoy EC: Endothelial injury in scleroderma. A protease mechanism. J Lab Clin Med 101:553-560, 1983
26. Kantor TV, Friberg D, Medsger TA Jr, Buckingham RB, Whiteside TL: Cytokine production and serum levels in Systemic Sclerosis. Clin Immunol Immunopathol 65:278-285, 1992
27. Kilbourne EM, Rigau-Perez JG, Heath CW Jr, Zack MM, Falck H, Martin-Marcos M, De Carlos A: Clinical epidemiology of toxic-oil syndrome: manifestations of a new illness. N Engl J Med 309:1408-1414, 1983
28. Krieg T, Meuer M: Systemic scleroderma. Clinical and pathophysiological aspects. J Am Acad Dermatol 18:457-481, 1988
29. Lau CS, Bridges AB, Muir A, Scott N, Bancroft A, Belch JF: Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br J Rheumatol 31:375-380, 1992
30. LeRoy EC, Medsger TA: Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 10:485-488, 1992
31. LeRoy EC, Black CM, Fleischmajer R, et al: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 12:217-223, 1988
32. Maricq HR, LeRoy EC: Progressive systemic sclerosis: disorders of the microcirculation. Clin Rheum Dis 5:81-101, 1979
33. 2 production by human neutrophils. The preparation and assay of NADPH oxidase-containing particles from human neutrophils. Meth Enzymol 105:358-365, 1984
34. Marks RM, Czemiecki M, Andrews BS, Penny R: The effects of scleroderma serum on human microvascular endothelial cells. Induction of antibody-dependent cellular cytotoxicity. Arthritis Rheum 31:1524-1534, 1988
35. Masi AT, Rodnan T, Medseger TA Jr, et al: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590, 1980
36. Murrel DF: A radical proposal for the pathogenesis of Scleroderma. J Am Acad Dermatol 28:78-85, 1993
37. Murrel GAG, Francis MJO, Bromley L: Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 265:259-265, 1990
38. Prescott RJ, Freemont AJ, Jones CJP, Hoyland J, Fielding P: Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166:255-263, 1992
39. Rodnan GP, Benedek TG, Medsger TA Jr, Cammarata RJ: The association of PSS with coal miners' pneumoconiosis and other forms of silicosis. Ann Intern Med 6:323-324, 1967
40. Rodnan GP, Myerowitz KC, Justh GO: Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma] and Raynaud's phenomenon. Medicine 59:393-408, 1980
41. - forming NADPH oxidase of phagocytes: nature, mechanisms of activation and function. Biochim Biophys Acta 853:65-89, 1986
42. Salojin, KV, Le Tonqueze M, Saraux A, Nassonov EL, Dueymes M, Piette JC, Youinou PY: Antiendothelial cell antibodies: useful markers of systemic sclerosis. Am J Med 102:178-185, 1997
43. Shingu M, Yoshioka K, Nobunaga M, Yoshida K: Human vascular smooth muscle cells and endothelial cells lack catalase activity and are susceptible to hydrogen peroxide. Inflammation 9:309-320, 1985
44. Silman AJ: Scleroderma-dermographics and survival. J Rheumatol 24:58-61, 1997
45. Steen VD, Medsger JA Jr: Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am 16:1-10, 1990
46. Stein CM, Tanner SB, Awad JA, Roberts LJ, Morrow JD: Evidence of free-radical-mediated injury (isoprostane overproduction) in Scleroderma. Arthritis Rheum 39:1146-1150, 1996
47. Sternberg EM, van Woert MH, Young SN, Magnussen I, Baker H, Gauthier S, Osterland K: Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med 303:782-787, 1980
48. Tsunawaki S, Sporn N, Ding A, Nathan C: Deactivation of macrophages by transforming growth factor-B. Nature 334:260-262, 1988
49. Umehara H, Kumagai S, Murakami M, Suginoshita E, Imura H: Enhanced production of interleukin 1 and tumor necrosis factor α by cultured peripheral blood monocytes from patients with sclerodenna. Arthritis Rheum 33:893-897, 1990
50. Varga J, Schumacher RH, Jimenez SA: Systemic Sclerosis after augmentation mammoplasty with silicone implants. Ann Intern Med 111:377-383, 1989
51. Weening KS, Wever R, Roos D: Quantitative aspects of the production of superoxide radicals by phagocytizing human granulocytes. J Lab Clin Med 85:245-252, 1975
52. White B: Immunopathogenesis of systemic sclerosis. Rheum Dis Clin North Am 22:675-694, 1996